Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients

References

• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999;159:813–18
   PubMed Web of Science ®Google Scholar
• Clouse JC, Osterhaus JT. Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659–64
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Winner, PK, Chmiel, JJ. Migraine preventive medication reduces resource utilization. Headache 2003;43:171–8
   PubMed Web of Science ®Google Scholar
• Redillas C, Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache 2000;40:83–102
   PubMed Web of Science ®Google Scholar
• Adelman JU, Von Seggern R. Cost considerations in headache treatment. Part 1: Prophylactic migraine treatment. Headache 1995;35: 479–87
   PubMed Web of Science ®Google Scholar
• Archibald N, Lipscomb J, McCrory D. Resource utilization and costs of care for treatment of chronic headache. Technical review 2.1 [online]. February 1999. Prepared for the Agency for Health Care Policy and Research under Contract No 290–94–2025. Available from http://www.clinpol.mc.duke.edu/Pubs/Publications/Resource_Manuscript.pdf [Accessed 6 June 2003]
   Google Scholar
• Clarke CE, MacMillan L, Sondhi S, Wells NEJ. Economic and social impact of migraine. Q J Med 1996;89:77–84
   Google Scholar
• Rasmussen BK, Jensen R, Olesen J. Impact of headache on sickness absence and utilisation of medical services: a Danish population study. J Epidemiol Commun Health 1992;46:443–6
   PubMed Web of Science ®Google Scholar
• Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ. Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 1993;20:131–7
   PubMed Web of Science ®Google Scholar
• Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselbled V. Drug treatments for the prevention of migraine headache. Technical review 2.3 [online]. February 1999. Prepared for the Agency for Health Care Policy and Research under Contract No. 290–94–2025. 1999. Available from http://www.clinpol.mc.duke.edu/Pubs/Publications/Drug_ Manuscript.pdf [Accessed 6 June 2003]
   Google Scholar
• Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003;43:36–43
   PubMed Web of Science ®Google Scholar
• Adelman JU, Adelman LC, Von Seggern R. Cost-effectiveness of antiepileptic drugs in migraine prophylaxis. Headache 2002;42:978–83
   PubMed Web of Science ®Google Scholar
• Adelman JU, Brod A, Von Seggern RL, Mannix LK, Rapoport AM. Migraine preventive medications: a reappraisal. Cephalalgia 1998;18:605–11
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kaup AO. The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002; 4:365–73
   PubMedGoogle Scholar
• Silberstein SD. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2001;2:1649–54
   PubMedGoogle Scholar
• Barrientos N, Chana P. Efficacy and safety of botulinum toxin A (BOTOX®) in the prophylactic treatment of migraine [abstract]. Headache 2002;42:452
   Google Scholar
• Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A (BOTOX®) in the prophylactic treatment of migraine. Poster presented at 44th Annual Scientific Meeting, American Scientific Society, June 21–23, 2002, Seattle, Washington
   Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S, for the BOTOX® Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445–50
   Google Scholar
• Mathew N, Kallasam K, Meadors L. ‘Disease modification’ in chronic migraine with botulinum toxin type A: long-term experience [abstract]. Headache 2002;42: 454
   Google Scholar
• Blumenfeld A. Decrease in headache medication use and cost after botulinum toxin type A (BOTOX®) treatment in a high triptan use population [abstract]. Headache 2002;42:420
   Google Scholar
• Stang PE, Osterhaus JT, Celentano DD. Migraine. Patterns of healthcare use. Neurology 1994;44(6 Suppl 4):S47–55
   Google Scholar
• Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159:857–63
   PubMed Web of Science ®Google Scholar
• Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000;40:300–5
   PubMed Web of Science ®Google Scholar
• Göbel H, Lindner V, Krack P, Heinze A, Gaartz N, Deuschl G. Treatment of chronic tension-type headache with botulinum toxin [abstract]. Cephalalgia 1999;19:455
   Web of Science ®Google Scholar
• Schmitt WJ, Slowey E, Fravi N, Weber S, Burgunder JM. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001;41:658–64
   PubMed Web of Science ®Google Scholar
• Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146–68
   PubMedGoogle Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754–63
   PubMed Web of Science ®Google Scholar
• Celentano DD, Stewart WF, Lipton RB, Reed ML. Medication use and disability among migraineurs: a national probability sample survey. Headache 1992;32:223–8
   PubMed Web of Science ®Google Scholar